Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
COCH vs BVS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)
BVS Overall Winner
6-Pillar Tally: COCH 1 – 5 BVS
Matrix Metrics: COCH 2 – 8 BVS
As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin).
- Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. COCH 35.1/100 SELL) and 0.85β · 74% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About COCH vs BVS
COCH
Envoy Medical, Inc. Class A Common Stock
$6.70
+0.0% 1D
Market Cap
$51.9M
TTM Revenue
$231,000
Forward P/E
N/M
Beta / 30D Vol
4.94β · 3352% Vol
Unified Composite Score
35.1
SELL
Tech 50.0
Fund 27.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
BVS
Head-to-Head Winner
Bioventus Inc. Class A Common Stock
$9.88
-0.7% 1D
Market Cap
$681.3M
TTM Revenue
$586M
Forward P/E
11.1x
Beta / 30D Vol
0.85β · 74% Vol
Unified Composite Score
46.2
HOLD
Tech 35.0
Fund 49.0
Flow 64.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (COCH 1 – 5 BVS)
1. Valuation Multiples
BVS
Forward P/E
N/M
11.1x
Trailing P/E
N/M
12.3x
PEG Ratio
N/M
1.20x
EV / Revenue
119.2x
1.5x
2. Growth & Scale
BVS
Revenue Growth (YoY)
+57.1%
+2.7%
Earnings Growth (YoY)
+0.0%
+69.7%
TTM Revenue (USD)
$231,000
$586M
Market Cap
$51.9M
$681.3M
3. Profitability & Quality
BVS
Gross Margin
N/A
68.7%
Operating Margin
-10261.0%
10.1%
Net Profit Margin
0.0%
9.8%
Return on Equity (ROE)
0.0%
25.8%
4. Balance Sheet & Cash Flow
BVS
Cash Generation (TTM)
-$21M
$85M
Cash Flow Margin
N/A
14.5%
Net Cash / Leverage
$24M Net Cash
$199M Net Debt (0.96x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
COCH
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
448.1% (100th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
BVS
OpEx & R&D Intensity
N/A
58.6% of Rev ($343M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: COCH (2) vs BVS (8)| Institutional Metric | COCH | BVS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $51.9M | $681.3M | BVS | |
| Trailing P/E Ratio | N/M | 12.3x | BVS | |
| Forward P/E Ratio | N/M | 11.1x | BVS | |
| Revenue Growth (YoY) | +57.1% | +2.7% | COCH | |
| Operating Margin (TTM) | -10261.0% | 10.1% | BVS | |
| Net Profit Margin | 0.0% | 9.8% | BVS | |
| Return on Equity (ROE) | 0.0% | 25.8% | BVS | |
| 52-Week Range Position | 89% ($0–$7) | 36% ($6–$16) | COCH | |
| Beta / 30D Volatility | 4.94β · 3352% Vol | 0.85β · 74% Vol | BVS | |
| Unified Institutional Score | 35.1 / 100 (SELL) | 46.2 / 100 (HOLD) | BVS | |
| Trailing 12M Revenue (USD) | $231,000 | $586M | Scale | |
| Gross Profit Margin (TTM) | N/A | 68.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 119.2x EV/Rev | 1.20x PEG · 1.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$21M ($24M Net Cash) | $85M ($199M Net Debt (0.96x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
COCH +1058.66 pp
3M Horizon
COCH +827.41 pp
6M Horizon
COCH +838.52 pp
1Y Horizon
COCH +796.38 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | COCH Revenue | BVS Revenue | COCH Op. Margin | BVS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $340M | N/A | 9.2% | BVS |
| FY2020 | N/A | $320M | N/A | 6.6% | BVS |
| FY2021 | N/A | $430M | N/A | 2.8% | BVS |
| FY2022 | $0M | $510M | -3673.4% | -32.7% | BVS |
| FY2023 | $0M | $510M | -5809.8% | -16.0% | BVS |
| FY2024 | $0M | $570M | -8558.2% | -2.7% | BVS |
| FY2025 | $0M | $570M | -9240.7% | 9.5% | BVS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
COCH
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BVS
BREAKDOWN
Current IV
448.1%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
COCH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BVS Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
58.6% of Rev ($343M)
90D Engineering Disclosures
0 Published
Investor FAQ COCH vs BVS Key Questions & Quantitative Answers
As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. COCH 35.1/100 SELL) and 0.85β · 74% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BVS leads the Growth & Scale pillar: COCH posts +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin), compared with BVS at +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), COCH cumulative revenue shifted N/A while BVS shifted +67.6%. In operating R&D and SG&A reinvestment, COCH deploys N/A (0 90-day corporate R&D disclosures) versus 58.6% of Rev ($343M) (0 disclosures) for BVS.
BVS screens cheaper on headline valuation multiples. COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin), whereas BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCH (0.0% ROE) versus BVS (25.8% ROE) capital efficiency.
In options market volatility and institutional positioning, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk). By comparison, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BVS vs COCH · Reverse Pair
BVS vs AVAH
· Sector Peer
BVS vs ANNX
· Sector Peer
BVS vs TMCI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking